Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Community Oncology Empowered: AllyGPO & BioCareSD Partner to Bring Choice and Growth


TEMPE, Ariz., April 4, 2024 /PRNewswire/ -- AllyGPO, a new specialty Group Purchasing Organization (GPO), and BioCareSD, a leading nationwide specialty distributor, announced their partnership at the 2024 Community Oncology Conference (April 4-5, Orlando, Florida). This collaboration creates a new choice for independent community practices.

AllyOncology, part of AllyGPO, is a technology-driven GPO focused solely on community oncology. This singular focus, combined with guidance from practice stakeholders and oncology experts, allows AllyGPO to implement strategies that support the viability and growth of community oncology care.

"The market demand for an alternative is clear," said Brian Ansay, AllyGPO CEO. "Our growing membership shows oncology practices seek an ally who brings new investment, technology, and a mission to preserve their independence."

BioCareSD, known for its personalized service with 40+ years of experience delivering rare, ultra-rare, and orphan disease therapies, has expanded into oncology drugs. This leverages their agile distribution network and broadens their reach to millions of patients with cancer.

"It's an exciting time for BioCare. Our investment in people and infrastructure and alignment with AllyGPO strengthens our position for rapid growth," remarked BioCare Board Chair James Frary. "Together we deliver real value to oncology practices. BioCareSD offers competitive drug pricing and outstanding customer service. AllyGPO's contracts and progressive technology empower practices to optimize their drug management."

AllyGPO and BioCareSD's nimble, transparent operations appeal to practices and biopharmaceutical companies. They value AllyGPO's investment in analytics that help providers navigate the growing complexity of oncology treatments and the appropriate use of products.

NewOncologyPartner.com enables practices to receive updates on BioCareSD's expanding product portfolio and highlights AllyIQtm, AllyGPO's specialty drug management platform. Designed for today's community oncology practice, AllyIQ integrates with existing systems for intelligent inventory management and offers a modern, modular oncology drug cabinet and role-based workflows to enhance staff productivity. AllyIQ's real-time, self-serve reports empower practices to maximize contract opportunities, enhance revenue cycle management, and improve cash flow.

About BioCareSD
Since 1982, BioCareSD, a BioCare company, has offered providers and their patients across the country fast and easy access to life-saving medications. This is accomplished via their wide-reaching, nationwide network of distribution centers and agile distribution capabilities offering both STAT and emergency deliveries. Headquartered in Tempe, Arizona, BioCareSD has a centralized customer support team and local, field-based account management teams both known for high-touch, responsive service. In 2023, BioCare was named to the Financial Times List of the Americas' Fastest Growing Companies, Inc. 5000's Fastest-Growing Private Companies in America, and the Inc. Power Partners Award list. For more information, please visit www.biocaresd.com.

About AllyGPO

AllyOncology is a member of the AllyGPO family of specialty-specific group purchasing organizations that champion community-based care. Built on the values of transparency and partnership, AllyGPO is guided by oncology providers and a leadership team with more than 170 years of combined specialty GPO, supply chain, and IT management experience. Members benefit from the GPO's ongoing investment in modern technology solutions and robust industry relationships. Learn more about how we are community built and community strong at www.AllyGPO.com.

Media Contact:
Dara Shulman
866-255-9476
[email protected] 

SOURCE AllyGPO | BioCareSD


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: